No effect of high-dose vitamin D supplementation on glycemic status or cardiovascular risk factors in subjects with prediabetes

Diabetes Care

Volumn 37, Issue 8, 2014, Pages 2123-2131

  Sollid, Stina Therese ^a,b   Hutchinson, Moira Y S ^a,b   Fuskevåg, Ole M ^b   Figenschau, Yngve ^a,b   Joakimsen, Ragnar M ^a,b   Schirmer, Henrik ^a   Njølstad, Inger ^a   Svartberg, Johan ^a,b   Kamycheva, Elena ^a,b   Jorde, Rolf ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CALCIUM ION; COLECALCIFEROL; ERGOCALCIFEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PLACEBO; TRIACYLGLYCEROL; 25 HYDROXYERGOCALCIFEROL; 25-HYDROXYVITAMIN D; CALCIFEDIOL; LIPID; VITAMIN; VITAMIN D;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; ORAL GLUCOSE TOLERANCE TEST; PARATHYROID HORMONE BLOOD LEVEL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIET SUPPLEMENTATION; DIET THERAPY; DOUBLE BLIND PROCEDURE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; PREDIABETIC STATE; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; VITAMIN D DEFICIENCY; YOUNG ADULT;

25-HYDROXYVITAMIN D 2; ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CALCIFEDIOL; CHOLECALCIFEROL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; PREDIABETIC STATE; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS; YOUNG ADULT;

EID: 84905046558     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0218     Document Type: Article

References (50)

1. Whiting DR, Guariguata L, Weil C., Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-321
2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234
3. World Health Organization. Diabetes fact sheet no. 312 [article online], 2013. Available from http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed 31 March 2014
4. Knowler WC, Barrett-Connor E, Fowler S.E., et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
5. Pan XR, Li GW, Hu Y.H., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-544
6. Tuomilehto J, Lindström J, Eriksson J.G., et al.; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350
7. Buchanan TA, Xiang AH, Peters R.K., et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796-2803
8. Carlsson LMS, Peltonen M, Ahlin S., et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 2012; 367: 695-704
9. DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care 2011; 34(Suppl. 2): S202-S209
10. Wing RR; Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170: 1566-1575
11. Pittas AG, Lau J, Hu F.B., Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007; 92: 2017-2029
12. Hossein-nezhad A., Holick MF Vitamin D for health: a global perspective. Mayo Clin Proc 2013; 88: 720-755
13. Liu E, Meigs JB, Pittas A.G., et al. Plasma 25-hydroxyvitamin D is associated with markers of the insulin resistant phenotype in nondiabetic adults. J Nutr 2009; 139: 329-334
14. Jorde R, Grimnes G. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res 2011; 50: 303-312
15. Anderson JL, May HT, Horne B.D., et al.; Intermountain Heart Collaborative (IHC) Study Group. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol 2010; 106: 963-968
16. Song Y, Wang L, Pittas A.G., et al. Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care 2013; 36: 1422-1428
17. von Hurst P.R., Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial. Br J Nutr 2010; 103: 549-555
18. Belenchia AM, Tosh AK, Hillman L.S., Peterson CA. Correcting vitamin D insufficiency improves insulin sensitivity in obese adolescents: a randomized controlled trial. Am J Clin Nutr 2013; 97: 774-781
19. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia [article online], 2006. Available from http://www.who.int/diabetes/publications/diagnosis-diabetes2006/en/index.html. Accessed 31 March 2014
20. Jacobsen BK, Eggen AE, Mathiesen E.B., Wilsgaard T., Njølstad I. Cohort profile: the Tromsø Study. Int J Epidemiol 2012; 41: 961-967
21. Hutchinson MS, Figenschau Y, Almas B., Njolstad I, Jorde R. Serum 25-hydroxyvitamin D levels in subjects with reduced glucose tolerance and type 2 diabetes - the Tromsø OGTT-study. Int J Vitam Nutr Res 2011; 81: 317-327
22. Sneve M, Figenschau Y, Jorde R. Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects. Eur J Endocrinol 2008; 159: 675-684
23. Melsom T, Mathisen UD, Eilertsen B.A., et al. Physical exercise, fasting glucose, and renal hyperfiltration in the general population: the Renal Iohexol Clearance Survey in Tromsø 6 (RENIS-T6). Clin J Am Soc Nephrol 2012; 7: 1801-1810
24. Hutchinson MS, Grimnes G, Joakimsen R.M., Figenschau Y., Jorde R. Low serum 25-hydroxyvitamin D levels are associated with increased allcause mortality risk in a general population: the Tromsø study. Eur J Endocrinol 2010; 162: 935-942
25. Matthews DR, Hosker JP, Rudenski A.S., Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
26. Katz A, Nambi SS, Mather K, et al Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-2410
27. Vickers AJ, Altman DG Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ 2001; 323: 1123-1124
28. Rosen CJ, Adams JS, Bikle D.D., et al. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev 2012; 33: 456-492
29. Bland R, Markovic D, Hills C.E., et al. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol 2004; 89-90: 121-125
30. Norman AW, Frankel JB, Heldt A.M., Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980; 209: 823-825
31. Maestro B, Campión J, Dávila N, Calle C. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J 2000; 47: 383-391
32. Cheng Q, Boucher BJ, Leung PS Modulation of hypovitaminosis D-induced islet dysfunction and insulin resistance through direct suppression of the pancreatic islet renin-angiotensin system in mice. Diabetologia 2013; 56: 553-562
33. George PS, Pearson ER, Witham MD Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. Diabet Med 2012; 29: e142-e150
34. Mitri J, Muraru MD, Pittas AG Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr 2011; 65: 1005-1015
35. Pilz S, Gaksch M, O'Hartaigh B, Tomaschitz A, März W. The role of vitamin D deficiency in cardiovascular disease: where do we stand in 2013? Arch Toxicol 2013; 87: 2083-2103
36. Strobel F, Reusch J, Penna-Martinez M, et al. Effect of a randomised controlled vitamin D trial on insulin resistance and glucose metabolism in patients with type 2 diabetes mellitus. Horm Metab Res 2014; 46: 54-58
37. Pilz S, Kienreich K, Rutters F., et al. Role of vitamin D in the development of insulin resistance and type 2 diabetes. Curr Diab Rep 2013; 13: 261-270
38. Harris SS, Pittas AG, Palermo NJ A randomized, placebo-controlled trial of vitamin D supplementation to improve glycaemia in overweight and obese African Americans. Diabetes Obes Metab 2012; 14: 789-794
39. Davidson MB, Duran P, Lee M.L., Friedman TC. High-dose vitamin D supplementation in people with prediabetes and hypovitaminosis D. Diabetes Care 2013; 36: 260-266
40. Hoseini SA, Aminorroaya A, Iraj B., Amini M. The effects of oral vitamin D on insulin resistance in pre-diabetic patients. J Res Med Sci 2013; 18: 47-51
41. Afzal S, Brøndum-Jacobsen P, Bojesen SE, Nordestgaard BG. Vitamin D concentration, obesity, and risk of diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol 2014; 2: 298-306
42. Pilz S, Gaksch M, Tomaschitz A. Vitamin D and prevention of diabetes: is lifelong endogenous vitamin D needed? Lancet Diabetes Endocrinol 2014; 2: 267-268
43. Li YC, Kong J, Wei M., Chen ZF, Liu SQ, Cao LP. 1,25-dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238
44. Tamez H, Thadhani RI Vitamin D and hypertension: an update and review. Curr Opin Nephrol Hypertens 2012; 21: 492-499
45. Forman JP, Scott JB, Ng K, et al Effect of vitamin Dsupplementation on blood pressure in blacks. Hypertension 2013; 61: 779-785
46. Larsen T, Mose FH, Bech J.N., Hansen AB, Pedersen EB. Effect of cholecalciferol supplementation during winter months in patients with hypertension: a randomized, placebo-controlled trial. Am J Hypertens 2012; 25: 1215-1222
47. Schnatz PF, Jiang X, Vila-Wright S, et al. Calcium/vitamin D supplementation, serum 25-hydroxyvitamin D concentrations, and cholesterol profiles in the Women's Health Initiative calcium/vitamin D randomized trial. Menopause 3 March 2014 [Epub ahead of print]
48. Heaney RP. Guidelines for optimizing design and analysis of clinical studies of nutrient effects. Nutr Rev 2014; 72: 48-54
49. Gallagher JC. Vitamin D deficiency and muscle strength: are they related? J Clin Endocrinol Metab 2012; 97: 4366-4369
50. Kupferschmidt K. Uncertain verdict as vitamin D goes on trial. Science 2012; 337: 1476-1478